Amylyx Q2 net loss $72.7M; revenue negative after RELYVRIO withdrawal; avexitide acquisition

Amylyx Pharmaceuticals, Inc.

2024-Q2 EPS reported -$2.82 revenue$87,620,000

Q2 net loss $72.7M ($1.07/share) vs net income $22.1M ($0.31) a year ago; revenue negative $(1.0)M after RELYVRIO/ALBRIOZA withdrawal.
Cash $309.8M at June 30, down from $373.3M at March 31; runway into 2026.
Acquired avexitide (GLP-1 antagonist) with FDA Breakthrough Therapy; PBH Phase 3 plan Q1 2025.
Restructuring $22.9M largely severance; headcount reduced after PHOENIX failure and product discontinuation.
R&D down to $23.3M, SG&A to $21.6M; cost cuts and pipeline shift from RELYVRIO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.